Literature DB >> 10952620

In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.

M J Ruiz-Serrano1, L Alcalá, L Martínez, M Díaz, M Marín, M J González-Abad, E Bouza.   

Abstract

Two hundred fifty isolates of Mycobacterium tuberculosis were evaluated for susceptibility to ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, trovafloxacin, and gemifloxacin (SB-265805). Levofloxacin, ciprofloxacin, and grepafloxacin showed the greatest activity (MIC for 90% of strains tested [MIC(90)] 1 microg/ml), although ofloxacin also showed good activity, with an MIC(90) of 2 microg/ml. Trovafloxacin and gemifloxacin showed lower in vitro activity, with MIC(90)s of 64 and 8 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952620      PMCID： PMC90110          DOI： 10.1128/AAC.44.9.2567-2568.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Drug-resistant TB may bring epidemic.

Authors:  B J Culliton
Journal:  Nature       Date:  1992-04-09       Impact factor: 49.962

2.  In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.

Authors:  S E Hoffner; L Gezelius; B Olsson-Liljequist
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

3.  Tuberculosis: a global overview of the situation today.

Authors:  P Sudre; G ten Dam; A Kochi
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

4.  [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].

Authors:  N Yamane; B Z Chilima; M Tosaka; Y Okazawa; K Tanno
Journal:  Kekkaku       Date:  1996-08

5.  Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

Authors:  N Kennedy; R Fox; G M Kisyombe; A O Saruni; L O Uiso; A R Ramsay; F I Ngowi; S H Gillespie
Journal:  Am Rev Respir Dis       Date:  1993-12

6.  Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

Authors:  M Tsukamura; E Nakamura; S Yoshii; H Amano
Journal:  Am Rev Respir Dis       Date:  1985-03

7.  The emergence of drug-resistant tuberculosis in New York City.

Authors:  T R Frieden; T Sterling; A Pablos-Mendez; J O Kilburn; G M Cauthen; S W Dooley
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

Review 8.  Activity of quinolones against mycobacteria.

Authors:  M R Jacobs
Journal:  Drugs       Date:  1995       Impact factor: 9.546

9.  In-vitro activity of quinolones and macrolides against mycobacteria.

Authors:  W W Yew; L J Piddock; M S Li; D Lyon; C Y Chan; A F Cheng
Journal:  J Antimicrob Chemother       Date:  1994-09       Impact factor: 5.790

10.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.

Authors:  M Goble; M D Iseman; L A Madsen; D Waite; L Ackerson; C R Horsburgh
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245
View more
  10 in total

Review 1.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

2.  Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.

Authors:  Hana M El Sahly; Larry D Teeter; Kenneth C Jost; Denise Dunbar; Justin Lew; Edward A Graviss
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

4.  Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.

Authors:  Cynthia A Sanders; Rachel R Nieda; Edward P Desmond
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

5.  Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors:  Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

6.  Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.

Authors:  Martin Bråbäck; Kristian Riesbeck; Arne Forsgren
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

7.  Clinical effects of gemifloxacin on the delay of tuberculosis treatment.

Authors:  Seo Yun Kim; Jae-Joon Yim; Jong Sun Park; Sung Soo Park; Eun Young Heo; Chang-Hoon Lee; Hee Soon Chung; Deog Kyeom Kim
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

8.  Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Augustine F B Cheng; Wing W Yew; Edward W C Chan; Miu L Chin; Mamie M M Hui; Raphael C Y Chan
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG.

Authors:  Chathurada Gajadeera; Melisa J Willby; Keith D Green; Pazit Shaul; Micha Fridman; Sylvie Garneau-Tsodikova; James E Posey; Oleg V Tsodikov
Journal:  J Antibiot (Tokyo)       Date:  2014-09-24       Impact factor: 2.649

10.  Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Hyejin Kim; Minji Seo; Young Kil Park; Jae-Il Yoo; Yeong Seon Lee; Gyung Tae Chung; Sungweon Ryoo
Journal:  Tuberc Res Treat       Date:  2013-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.